Edesa Biotech, Inc.
$6.75
▲
10.63%
2026-04-21 06:34:00
www.edesabiotech.com
NCM: EDSA
Explore Edesa Biotech, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$49.5 M
Current Price
$6.75
52W High / Low
$9.37 / $0.72
Stock P/E
—
Book Value
$0.56
Dividend Yield
—
ROCE
-57.24%
ROE
-96.39%
Face Value
—
EPS
$-1.07
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
-0.68
Debt / Equity
0
Current Ratio
16.82
Quick Ratio
10.67
Forward P/E
-2.86
Price / Sales
—
Enterprise Value
$43.33 M
EV / EBITDA
-5.25
EV / Revenue
—
Rating
None
Target Price
$11
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Propanc Biopharma, Inc. | $0.12 | — | $2.33 M | — | -407.57% | -18.12% | $11 / $0.1 | $0.78 |
| 2. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 3. | Virax Biolabs Group Limited | $0.14 | — | $1.05 M | — | -107.11% | -83.82% | $1.2 / $0.1 | $0.81 |
| 4. | Revolution Medicines, Inc. | $143.09 | — | $30.24 B | — | -57.28% | -58.07% | $155.7 / $34 | $8.28 |
| 5. | Connect Biopharma Holdings Limited | $2.68 | — | $158.82 M | — | -24.19% | -82.72% | $3.82 / $0.65 | $0.74 |
| 6. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 7. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.24 M | -2.22 M | -1.72 M | -1.59 M | -1.6 M | — |
| Net Profit | -2.25 M | -2.23 M | -1.75 M | -1.59 M | -1.62 M | — |
| EPS in Rs | -0.25 | -0.25 | -0.2 | -0.18 | -0.18 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -7.13 M | -6.32 M | -8.64 M | -17.59 M |
| Net Profit | -7.19 M | -6.17 M | -8.37 M | -17.55 M |
| EPS in Rs | -0.81 | -0.69 | -0.94 | -1.97 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 13.53 M | 3.81 M | 8.89 M | 11.58 M |
| Total Liabilities | 1.08 M | 1.83 M | 1.84 M | 2.18 M |
| Equity | 12.45 M | 1.98 M | 7.05 M | 9.39 M |
| Current Assets | 11.51 M | 1.68 M | 6.44 M | 9.09 M |
| Current Liabilities | 1.08 M | 1.83 M | 1.82 M | 2.14 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.32 M | -4.89 M | -6.64 M | -12.28 M |
| Investing CF | — | — | 0 M | -0.01 M |
| Financing CF | 17.03 M | 0.59 M | 4.83 M | 11.63 M |
| Free CF | -7.32 M | -4.89 M | -6.64 M | -12.28 M |
| Capex | — | — | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 26.32% | 52.28% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-10-11 | 1:0.142857 |